Abstracts tagged "pregnancy"

Abstract Number: 2222 • ACR Convergence 2025
Neonatal Myocardial Strain in Offspring born to Mothers with Systemic Lupus Erythematosus: Pilot Data from the LEGACY Cohort
Reem Farhat¹, Lawrence Rudski², Natalie Dayan³, Catherine Henin⁴, Daniela Villegas Martinez⁴, Sariya Sahussarungsi¹, Pasinee Kanaprach¹, Sasha Bernatsky⁵, Gabriel Altit⁴ and Evelyne Vinet⁵, ¹McGill University, Faculty of Medicine and Health Sciences, Montreal, QC, Canada, ²Jewish General Hospital, Montreal, QC, Canada, ³McGill University Health Centre, Montreal, QC, Canada, ⁴Montreal Children's Hospital, Montreal, QC, Canada, ⁵Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) increases the risk of placenta-mediated adverse pregnancy outcomes (APO) and may impact offspring cardiovascular health. Transplacental maternal anti-Ro antibodies can…
Abstract Number: 2202 • ACR Convergence 2025
Epidemiologic Evaluation of Postpartum Mental Health for Women Living with Systemic Lupus Erythematosus: A Population-Based Cohort Study Among Medicaid Enrollees
Alyssa Howren¹, Amadeia Rector², Sadaf Sediqi³ and Julia F Simard⁴, ¹Stanford University, Menlo Park, CA, ²Stanford University, San Francisco, CA, ³Stanford University, Palo Alto, CA, ⁴Stanford Medicine, Stanford, CA
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem autoimmune rheumatic disease, predominately affecting women during their reproductive years. Despite widespread evidence that individuals with SLE…
Abstract Number: 0855 • ACR Convergence 2025
Certolizumab Pegol to Prevent Adverse Pregnancy Outcomes in Patients with Antiphospholipid Syndrome and Lupus Anticoagulant (IMPACT): Results from Ongoing Recruitment of a Prospective, Single-Arm, Open-Label, Phase 2 Trial
Jane Salmon¹, Mimi Kim², Marta Guerra¹, Joseph Worden³, Carl Laskin⁴, Maria DeSancho⁵, Inna Landres⁵, Jason S. Knight⁶, Haley Slosberg¹, Margaret Minett¹ and Ware Branch⁷, ¹Hospital for Special Surgery, New York, NY, ²Albert Einstein College of Medicine, Bronx, NY, ³University of Utah School of Medicine, Salt Lake City, ⁴University of Toronto, Toronto, ON, Canada, ⁵Weill Cornell Medicine, New York, ⁶University of Michigan, Ann Arbor, MI, ⁷University of Utah Health Sciences Center, Salt Lake City, UT
Background/Purpose: The IMPACT trial (NCT03152058) showed that certolizumab appears effective in preventing placenta-mediated adverse pregnancy outcome (APO) in high-risk antiphospholipid syndrome (APS) patients. We have…
Abstract Number: PP03 • ACR Convergence 2025
My Journey of Risk, Loss, and Hope: The Role of Multidisciplinary Collaboration in Managing Pregnancy with Takayasu Arteritis
Tugce Turten Kaymaz
Background/Purpose: At the age of 26, the same month I got married, I was diagnosed with Takayasu Arteritis following severe chest and back pain. Hypertension…
Abstract Number: 2221 • ACR Convergence 2025
Racial Differences in Cardiovascular Events and Adverse Pregnancy Outcomes Among Pregnant Individuals With Systemic Lupus Erythematosus
Rashmi Dhital¹, Rebecca Baer² and Christina Chambers³, ¹Vanderbilt University Medical Center, Brentwood, TN, ²University of California San Diego, San Diego, CA, ³University of California, San Diego, La Jolla, CA
Background/Purpose: Pregnant individuals with systemic lupus erythematosus (SLE) face an increased risk of cardiovascular events (CVEs) as well as adverse pregnancy outcomes (APOs). While racial…
Abstract Number: 2200 • ACR Convergence 2025
Obstetric and Neonatal Complications in Women living with Axial Spondyloarthritis: a population-based, matched cohort study
Sinead Maguire¹, John Snelgrove², Priscila Pequeno³, Michael Paterson⁴, Fangyun Wu⁴, Laura Passalent⁵, Anthony Perruccio⁶, Dharini Mahendira⁷, Elie Karam⁸, Robert Inman⁹ and Nigil Haroon¹⁰, ¹Our Lady's Hospital Navan, Dublin, Dublin, Ireland, ²Mount Sinai Hospital, Toronto, Canada, ³Institute for Clinical Evaluative Sciences (ICES), Toronto, Canada, ⁴Institute of Clinical & Evaluative Sciences, Toronto, Canada, ⁵Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, ⁶Schroeder Arthritis Institute and Krembil Research Institute, University Health Network, Toronto, Canada, ⁷St Michael's Hospital, Toronto, Canada, ⁸Canadian Spondylitis Association, Toronto, Canada, ⁹University Health Network, Toronto, ON, Canada, ¹⁰Department of Medicine/Rheumatology, University Health Network, Schroeder Arthritis Institute, University of Toronto, Toronto, ON, Canada
Background/Purpose: Women with axial spondyloarthritis (axSpA) are frequently diagnosed during their childbearing years. While studies have reported on pregnancy complications in this population, deriving generalizable…
Abstract Number: 0853 • ACR Convergence 2025
Olink Proteomics Identifies Macrophage Pro-inflammatory Proteins in Maternal Sera Predictive of Fetal Atrioventricular Block Independent of Maternal Health Status
Philip Carlucci¹, Mala Masson², Colin Phoon³, Ashley Roman³, Peter Izmirly⁴, Amit Saxena⁵, Michael Belmont⁶, Christina Penfield³, Young Mi Lee³, Julie Nusbaum⁶, Andrew Rubenstein³, Nalani Sachan³, Joel Guthridge⁷, Judith James⁷, Elena Sinkovskaya⁸, Alfred Abuhamad⁸, Gary Satou⁹, Whitnee Hogan¹⁰, Anita Moon-Grady¹¹, Lisa Howley¹², Mary Donofrio¹³, Stephanie Levasseur¹⁴, Miwa Geiger¹⁵, Sonal Owens¹⁶, Kristopher Cumbermack¹⁷, Jyothi Matta¹⁸, Gary Joffe¹⁹, Christopher Lindblade²⁰, Caitlin Haxel²¹, Katherine Kohari²², Joshua Copel²², James Strainic²³, Tam Doan²⁴, Conisha Holloman²⁴, Stacy Killen²⁵, Theresa Tacy²⁶, Michelle Kaplinski²⁶, Nicola Fraser³, Kelly Ruggles²⁷, Bettina Cuneo²⁸, Jill Buyon³ and Robert Clancy¹⁴, ¹New York University School of Medicine, New York, NY, ²NYU Langone Medical Center- Division of Rheumatology, New York, NY, ³NYU Grossman School of Medicine, New York, NY, ⁴New York University Grossman School of Medicine, New York, NY, ⁵Division of Rheumatology, Department of Medicine, NYU Grossman School of Medicine, New York, NY, ⁶NYU Langone Health, New York, NY, ⁷Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁸Eastern Virginia Medical School, Norfolk, VA, ⁹University of California Los Angeles, Los Angeles, CA, ¹⁰University of Utah, Salt Lake City, UT, ¹¹University of California San Francisco, San Francisco, CA, ¹²Midwest Fetal Care Center, Children's Minnesota/Allina Health, Minneapolis, MN, ¹³Children's National Hospital, Washington, DC, ¹⁴Columbia University, New York, NY, ¹⁵Mount Sinai School of Medicine, New York, NY, ¹⁶University of Michigan, Ann Arbo, MI, ¹⁷University of Kentucky, Lexington, KY, ¹⁸University of Louisville, Louisville, KY, ¹⁹Perinatal Associates of New Mexico, Albuquerque, NM, ²⁰Phoenix Children's Hospital, Phoenix, AZ, ²¹University of Vermont Children's Hospital, Burlington, VT, ²²Yale University, New Haven, CT, ²³UH Rainbow Babies, Cleveland, OH, ²⁴Baylor College of Medicine, Houston, TX, ²⁵Vanderbilt University, Nashville, TN, ²⁶Stanford University, Stanford, CA, ²⁷NYU Grossman School of Medicine, Brooklyn, NY, ²⁸University of Arizona College of Medicine, Tucson, AZ
Background/Purpose: Fetal atrioventricular block (fAVB) is presumed dependent on the transplacental passage of SSA/Ro52/60kD autoantibodies that bind to apoptotic fetal cardiomyocytes, triggering macrophage activation and…
Abstract Number: 2655 • ACR Convergence 2025
Fetal and maternal outcomes in systemic sclerosis and very early diagnosis of systemic sclerosis pregnancies, a national prospective study
Anne Murarasu¹, lauren beaudeau², Véronique Le Guern³, gaelle guettrot-Imbert³, claire cazalets⁴, cecile durant⁵, Cecile Yelnik⁶, Céline Roussin⁷, Marie-Charlotte Besse⁸, Emilie Berthoux⁹, Emmanuel Chatelus¹⁰, Eric Hachulla¹¹, Estibaliz LAZARO¹², Francois Maurier¹³, Gaelle leroux¹⁴, Grégory Pugnet¹⁵, Isabelle durieu¹⁶, Loic RAFFRAY¹⁷, Maelle Le Besnerais¹⁸, Mélanie roriz¹⁹, Odile SOUCHAUD-DEBOUVERIE²⁰, Patrick JEGO²¹, Pauline ORQUEVAUX²², Claire de Moreuil²³, Helene MAILLARD²⁴, Nathalie Morel²⁵, Anna Molto²⁶, Camille Le Ray²⁷, emmanuelle pannier²⁷, loic sentilhes²⁵, Luc Mouthon²⁸, Nathalie Costedoat-Chalumeau²⁹ and Benjamin Chaigne³⁰, ¹Tours University Hospital, Tours, France, ²Centre Hospitalier Ales Les Cevennes, Ales, France, ³Cochin hospital, Paris, France, ⁴Rennes Hospital, Rennes, France, ⁵Nantes University Hospital, Nantes, France, ⁶lille university, Lille, France, ⁷Centre Hospitalier Ouest Réunion, Saint Paul, France, ⁸Tours University Hospital, ³⁷⁰⁰⁰ tours, Ile-de-France, France, ⁹Internal Medicine, Saint Luc Saint Joseph Hospital, Lyon, France, ¹⁰Department of Rheumatology, University Hospital Strasbourg, France, Strasbourg, France, ¹¹University of Lille, LILLE, France, ¹²Bordeaux University Hospital, Pessac, France, ¹³HOPITAUX PRIVES DE METZ, Vaux / Frankreich, France, ¹⁴Pitié-Salpêtrière University Hospital, Paris, France, ¹⁵CHU Toulouse Rangueil Service de Medecine Interne et Immunologie Clinique, Toulouse, France, ¹⁶Lyon University Hospital, Lyon, France, ¹⁷Félix-Guyon University Hospital of La Réunion, Saint Denis, France, ¹⁸Rouen University Hospital, Rouen, France, ¹⁹Agen hospital, Agen, France, ²⁰Poitiers University Hospital, Poitiers, France, ²¹Rennes University Hospital, Rennes, France, ²²Reims University Hospital, Reims, France, ²³CHU DE BREST, BREST, France, ²⁴Lille University Hospital, Lille, France, ²⁵Bordeaux University Hospital, Bordeaux, France, ²⁶Assistance Publique Hôpitauxde Paris, Paris, France, ²⁷Cochin Port Royal University Hospital, Paris, France, ²⁸Hopital Cochin - Paris University, Paris, France, ²⁹Inserm DR Paris ⁵, Paris, France, ³⁰Cochin University Hospital, Paris, France
Background/Purpose: Pregnancy in women with systemic sclerosis (SSc) is considered high-risk due to complications like scleroderma renal crisis and preeclampsia, related to vasculopathy. Prospective data…
Abstract Number: 2219 • ACR Convergence 2025
Transcriptomic and Immune Landscape of Recurrent Pregnancy Loss and Unexplained Infertility in Systemic Lupus Erythematosus
Rodolfo Martinez-Canales¹, Braulio R. Avalos-Garcia², Andres M. Ortiz-Rios², Eva Abigaid Galindo-Calvillo², Lorena Perez-Barbosa², Dionicio A. Galarza-Delgado³, Cassandra Michele Skinner-Taylor², Mario Cesar Salinas-Carmona¹ and Noe Macias-Segura¹, ¹Immunology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico, ²Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico, ³Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico
Background/Purpose: Recurrent pregnancy loss (RPL) and unexplained infertility (UIF) are significant reproductive health challenges in patients with systemic lupus erythematosus (SLE). SLE causes systemic inflammation…
Abstract Number: 2199 • ACR Convergence 2025
Disparities in Reproductive Health Counseling Among Hispanic Women with Autoimmune Rheumatic Diseases: Insights from a Patient-Reported Survey in an Urban Safety-Net Setting
Eaman Alhassan¹, Laura Kobashigawa², Vanessa Ramos², Jack Rodman² and Leanna Wise³, ¹University of Pittsburgh Medical Center, Pittsburgh, PA, ²University of Southern California, Los Angeles, ³LAGMC/Keck Medicine of USC, Los Angeles
Background/Purpose: Reproductive-age Hispanic women with rheumatoid arthritis, juvenile idiopathic arthritis (combined, inflammatory arthritis; IA), and systemic lupus erythematosus (SLE) often bear a higher disease burden…
Abstract Number: 0794 • ACR Convergence 2025
Using Artificial Intelligence to Analyze Multilingual Qualitative Data in Lupus Pregnancy Research: A Proof of Concept with Large Language Models
Romina Boers¹, Grace Terry² and Bella Mehta³, ¹Weil Cornell Medicine, New York, ²Weil Cornell Medicine, Ne wYork, ³Hospital for Special Surgery, Weill Cornell Medicine, Jersey City, NJ
Background/Purpose: Women with systemic lupus erythematosus (SLE), particularly those of childbearing age, face heightened risks during pregnancy, including disease flares, adverse maternal-fetal outcomes, and emotional…
Abstract Number: 2632 • ACR Convergence 2025
Maternal vascular malperfusion: association with adverse perinatal outcomes in lupus pregnancies
ANA JIMENA LOPEZ DIAZ¹, MARIA DEL CARMEN ZAMORA MEDINA², Mario Isaac Lumbreras Márquez¹, Diana Yazmin Copado mendoza¹, Oralia Alejandra Orozco Guillén¹, Maria José rodríguez Sibaja¹, Martha Leticia Palafox Vargas¹ and Sandra Acevedo gallegos¹, ¹Instituto Nacional de Perinatología, Mexico City, Distrito Federal, Mexico, ²Instituto Nacional de Perinatologia, Mexico City, Distrito Federal, Mexico
Background/Purpose: Systemic lupus erythematosus (SLE) is associated with increased risk of adverse perinatal outcomes (APOs), including preeclampsia, preterm birth, fetal growth restriction, and stillbirth. Placental…
Abstract Number: 2218 • ACR Convergence 2025
Pregnancy Outcomes and Placental Findings in Women with IgA Vasculitis: A Case-Control Study
Edgar Iván Mendoza Ríos, María Del Carmen Zamora Medina, Mario Isaac Lumbreras Márquez, Diana Yazmin Copado mendoza, Oralia Alejandra Orozco Guillén, Maria José rodríguez Sibaja, Martha Leticia Palafox Vargas and Sandra Acevedo gallegos, Instituto Nacional de Perinatología, Mexico City, Distrito Federal, Mexico
Background/Purpose: IgA vasculitis (IgA-V) is a systemic vasculitis involving small vessels, most frequently affecting children. There is few information about pregnancy outcomes in women with…
Abstract Number: 2198 • ACR Convergence 2025
Sociocultural Influences on Pregnancy Planning for Individuals Diagnosed with SLE in an Urban Hispanic Population: A Qualitative Study with Considerations for a Holistic Approach
Andrew Ramirez¹, Alexa Montes de Oca¹, Martha Delgado¹, Mellissa withers¹ and Leanna Wise², ¹University of Southern California, Los Angeles, ²LAGMC/Keck Medicine of USC, Los Angeles
Background/Purpose: As systemic lupus erythematosus (SLE) often affects women of child-bearing age, understanding how this population makes reproductive health decisions is critical for well-rounded healthcare.…
Abstract Number: 0213 • ACR Convergence 2025
Development of a Predictive Tool for Obstetric Risk Stratification in Autoimmune Rheumatic Diseases: A Meta-Analysis-Based Model
Noe Macias-Segura¹, Rodolfo Martinez-Canales¹, Braulio R. Avalos-Garcia², Andres M. Ortiz-Rios², Eva Abigaid Galindo-Calvillo², Mario Cesar Salinas-Carmona¹, Lorena Perez-Barbosa², Dionicio A. Galarza-Delgado³ and Cassandra Michele Skinner-Taylor², ¹Immunology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico, ²Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico, ³Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico
Background/Purpose: Autoimmune rheumatic diseases (ARDs) such as systemic lupus erythematosus (SLE), antiphospholipid syndrome (APS), rheumatoid arthritis (RA), and Sjögren's syndrome significantly increase the risk of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].